Browsing by Author "Gelfand, Jeffrey"

Now showing items 1-4 of 4

    • Near-Infrared Laser Adjuvant for Influenza Vaccine 

      Kashiwagi, Satoshi; Yuan, Jianping; Forbes, Benjamin; Hibert, Mathew L.; Lee, Eugene L. Q.; Whicher, Laura; Goudie, Calum; Yang, Yuan; Chen, Tao; Edelblute, Beth; Collette, Brian; Edington, Laurel; Trussler, James; Nezivar, Jean; Leblanc, Pierre; Bronson, Roderick; Tsukada, Kosuke; Suematsu, Makoto; Dover, Jeffrey; Brauns, Timothy; Gelfand, Jeffrey; Poznansky, Mark C. (Public Library of Science, 2013)
      Safe and effective immunologic adjuvants are often essential for vaccines. However, the choice of adjuvant for licensed vaccines is limited, especially for those that are administered intradermally. We show that non-tissue ...

    • A Novel Laser Vaccine Adjuvant Increases the Motility of Antigen Presenting Cells 

      Chen, Xinyuan; Kim, Pilhan; Farinelli, Bill; Doukas, Apostolos; Yun, Seok-Hyun; Gelfand, Jeffrey Alan; Anderson, Richard Rox; Wu, Mei X. (Public Library of Science, 2010)
      Background: Development of a potent vaccine adjuvant without introduction of any side effects remains an unmet challenge in the field of the vaccine research. Methodology/Principal Findings: We found that laser at a specific ...

    • A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma 

      Yuan, Jianping; Kashiwagi, Satoshi; Reeves, Patrick; Nezivar, Jean; Yang, Yuan; Arrifin, Nadiah Hashim; Nguyen, Mai; Jean-Mary, Gilberte; Tong, Xiaoyun; Uppal, Paramjit; Korochkina, Svetlana; Forbes, Ben; Chen, Tao; Righi, Elda; Bronson, Roderick; Chen, Huabiao; Orsulic, Sandra; Brauns, Timothy; Leblanc, Pierre; Scholler, Nathalie; Dranoff, Glenn; Gelfand, Jeffrey; Poznansky, Mark C (BioMed Central, 2014)
      Background: Although dendritic cell (DC) vaccines are considered to be promising treatments for advanced cancer, their production and administration is costly and labor-intensive. We developed a novel immunotherapeutic ...

    • Risks Associated With Lentiviral Vector Exposures and Prevention Strategies 

      Schlimgen, Ryan; Howard, John; Wooley, Dawn; Thompson, Maureen; Baden, Lindsey R.; Yang, Otto O.; Christiani, David C.; Mostoslavsky, Gustavo; Diamond, David V.; Duane, Elizabeth Gilman; Byers, Karen; Winters, Thomas; Gelfand, Jeffrey A.; Fujimoto, Gary; Hudson, T. Warner; Vyas, Jatin M. (Lippincott Williams & Wilkins, 2016)
      Lentiviral vectors (LVVs) are powerful genetic tools that are being used with greater frequency in biomedical laboratories and clinical trials. Adverse events reported from initial clinical studies provide a basis for risk ...